FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesMedidata webinar - Evolution of Trial Virtualization & its Impact on Clinical Supplies
Topic: Supply Chain
Webinar
Free
Challenges of the Cell, Gene, CAR-T and Personalized Medicine Supply Chains
Topics: Cold Chain, Conference, Supply Chain
Video
Members
Commercialization of Personalized Medicines
Topic: Pharma Industry
Report
Members
